乌帕替尼(Upadacitinib hemihydrate) - 药物靶点：JAK1_在研适应症：巨细胞动脉炎，多关节型幼年特发性关节炎，活动性中度克罗恩病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Upadacitinib Hydrate、Upadacitinib tartrate、A-1293543.0

+ [6]

靶点

JAK1

作用方式

抑制剂

作用机制

JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂)

治疗领域

免疫系统疾病感染遗传病与畸形+ [9]

在研适应症

巨细胞动脉炎多关节型幼年特发性关节炎活动性中度克罗恩病+ [23]

非在研适应症

睡眠异常狼疮性肾炎

原研机构

AbbVie, Inc.

在研机构

AbbVie, Inc.

艾伯维医药贸易（上海）有限公司AbbVie Ltd. (South Korea)

+ [4]

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2019-08-16),

类风湿关节炎

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)、突破性疗法 (中国)、特殊审批 (中国)

登录后查看时间轴

结构/序列

分子式C34H40F6N12O3

InChIKeyGJMQTRCDSIQEFK-SCDRJROZSA-N

CAS号2050057-56-0

关联

173

项与乌帕替尼相关的临床试验

NCT06016517

/ Not yet recruitingN/AIIT

Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available. The treatments are different in how they work, the way they are given, side- effects, and cost. While treatment guidelines are available, finding the best treatment order of treatments is often based on physician choice. The main question this study aims to answer are:
* What are the effects of different treatments on RA symptoms and condition for each individual patient
* What is the effectiveness of different treatments across all patients enrolled in the N-of-1 study
Participants will be enrolled and randomized to a sequence of three U.S. Food and Drug Administration (FDA) approved RA medications: 1. etanercept, 2. adalimumab, 3. upadacitinib 4. tocilizumab. Participants will be asked to complete questionnaires about their condition and quality of life fortnightly, monthly and/or quarterly (either in clinic or remotely) and report their level of pain on alternate days (remotely).

开始日期2025-11-15

申办/合作机构

Tufts Medical Center, Inc.

NCT07018206

/ Not yet recruiting临床4期

Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (UP-FOR-U)

This is a Phase IV, open-label, multicenter study evaluating the impact of upadacitinib on the frequency of acute anterior uveitis (AAU) in adults with axial spondyloarthritis (axSpA) and a documented history of AAU in the prior 52 weeks. Approximately 200 participants will be enrolled across North America and Europe, including both biologic DMARD-inadequate responders (bDMARD-IR) and bDMARD-naïve patients. The primary objective is to assess the change in exposure-adjusted AAU event rate during 52 weeks of treatment with upadacitinib 15 mg once daily. Secondary objectives include evaluating the effect of upadacitinib on disease activity, pain, physical function, quality of life, and sleep. Safety and tolerability will also be assessed throughout the study.

开始日期2025-11-01

申办/合作机构

Canadian Research and Education (CaRE Arthritis).

CTR20253796

/ RecruitingN/A

乌帕替尼缓释片餐后生物等效性试验

主要研究目的评价中国健康成年受试者餐后条件下单次单剂量口服乌帕替尼缓释片受试制剂（规格：15mg，申办者：江苏万高药业股份有限公司）和参比制剂[商品名：瑞福®（RINVOQ®），规格：15mg，持证商：AbbVie Deutschland GmbH & Co. KG]后的药代动力学特点和生物等效性。次要研究目的研究乌帕替尼缓释片受试制剂（规格：15mg）和参比制剂[商品名：瑞福®（RINVOQ®），规格：15mg]在中国健康成年受试者中的安全性。

开始日期2025-09-15

申办/合作机构

江苏万高药业股份有限公司

100 项与乌帕替尼相关的临床结果

登录后查看更多信息

100 项与乌帕替尼相关的转化医学

登录后查看更多信息

100 项与乌帕替尼相关的专利（医药）

登录后查看更多信息

1,462

项与乌帕替尼相关的文献（医药）

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Clinical observation of 10 cases of stable non-segmental vitiligo in adults treated with upadacitinib

Article

作者: Li, Ruyi ; Zhang, Wen ; Yuan, Mingzhu ; Sun, Yi

OBJECTIVE:

To evaluate the efficacy and safety of upadacitinib in treating stable nonsegmental vitiligo in adults.

METHODS:

Data were collected from adult patients with stable nonsegmental vitiligo treated with upadacitinib at Jingzhou Hospital of Yangtze University between November 2023 and November 2024. Treatment efficacy was compared at 8 and 16 weeks and any adverse reactions were recorded.

RESULTS:

A total of 10 patients were included, 6 of whom also received 308 nm excimer laser therapy. A total of 200 lesions were observed, with 146 receiving additional laser therapy. After 8 weeks of treatment, 60.0% of lesions achieved at least 25% pigmentation, while 27.0% achieved more than 50% pigmentation. After 16 weeks, these rates increased to 78.0% and 52.5%, respectively. Treatment efficacy was greater at 16 weeks compared to 8 weeks (p < 0.001). Acral lesions showed lower response rates compared to lesions on the face, neck, trunk, and limbs (p < 0.05). There was no statistically significant difference in efficacy between upadacitinib monotherapy and combination therapy with phototherapy (p > 0.05). Among the 10 patients, 6 achieved over 50% improvement in total VASI score after 16 weeks, while 4 showed more than 75% improvement.

CONCLUSION:

Upadacitinib is safe and effective treatment for stable non-segmental vitiligo in adults.

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry

Article

作者: Vroman, Florence ; Loman, Laura ; de Bruin-Weller, Marjolein S. ; Schuttelaar, Marie-Louise L. A. ; Zuithoff, Nicolaas P. A. ; Kamsteeg, Marijke ; van der Rijst, Lisa P. ; de Graaf, Marlies ; Bacoş-Cosma, Octavian I. ; van Lumig, Paula P. M.

PURPOSE:

Upadacitinib is approved for treating moderate-to-severe atopic dermatitis (AD) aged ≥12 years. We evaluated upadacitinib's effectiveness and safety in AD adolescents in daily practice.

MATERIALS AND METHODS:

Fifteen adolescent AD patients from the BioDay registry, treated with upadacitinib 15 mg once daily were evaluated at baseline and after 4, 8, 16, and 28 weeks. Effectiveness was assessed using Eczema Area and Severity Index (EASI) score and Investigator Global Assessment (IGA) score. Patient-reported outcomes included Numeric Rating Scale (NRS) for pruritus and presence of sleep disturbance. Adverse events (AEs) were evaluated at each visit.

RESULTS:

Mean EASI score significantly decreased from 13.4 (95% CI 8.5-18.3) to 7.8 (95% CI 2.4-13.3) after 28 weeks (p = .002). Mean NRS pruritus significantly decreased from 6.5 (95% CI 4.9-8.2) to 4.8 (95% CI 3.0-6.6) after 28 weeks (p = .003). At week 16, 75.0% (95% CI 46.8-91.1) achieved EASI ≤7, and 50.0% (95% CI 25.4-74.6) achieved NRS pruritus ≤4. Overall, 31 AEs were reported in 10 patients (66.7%). Five patients (33.3%) discontinued treatment: two due to ineffectiveness, two due to AEs, and one due to laboratory monitoring problems.

CONCLUSIONS:

Our findings indicate that upadacitinib is effective and relatively safe for adolescents with moderate-to-severe AD; however, 33.3% discontinued treatment.

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Vitiligo exacerbation during upadacitinib treatment for atopic dermatitis and improvement following a switch to abrocitinib: a case report

Article

作者: Wang, Zhaoyang ; Wang, Meng ; Sun, Yonghu

AIM:

Janus kinase (JAK) inhibitors have emerged as targeted therapies for atopic dermatitis (AD), and increasing evidence suggests their potential benefit in vitiligo. While both diseases are considered immunologically distinct, recent insights point to overlapping cytokine pathways that may be modulated by JAK1-selective inhibitors.

MATERIALS AND METHODS:

We present a case of a 37-year-old male with moderate-to-severe AD and stable vitiligo who developed worsening of vitiligo following treatment with upadacitinib. Although AD symptoms resolved, vitiligo lesions progressed despite phototherapy.

RESULTS:

After switching from upadacitinib to abrocitinib, the patient experienced marked repigmentation of vitiligo lesions within three months, along with continued control of AD symptoms.

CONCLUSIONS:

This case highlights the differential effects of upadacitinib and abrocitinib, possibly due to their distinct JAK2 inhibition profiles. The findings underscore the importance of considering kinase selectivity when using JAK inhibitors in patients with overlapping immune-mediated skin disorders.

1,018

项与乌帕替尼相关的新闻（医药）

2025-10-14

·药时代

“药王的继承者”乌帕替尼适应症扩展获批

药时代寻找对创新药Biotech 实实在在感兴趣且资金充沛的投资公司请立即联系药时代BD团队（BD@drugtimes.cn）！正文共：1200字预计阅读时间：5分钟 2025年10月13日，艾伯维宣布，美国FDA批准了一项补充新药申请（sNDA），该申请更新了RINVOQ（乌帕替尼、upadacitinib）的适应症声明，用于治疗患有中度至重度活动性溃疡性结肠炎（UC）和中度至重度活动性克罗恩病（CD）的成人。此前，RINVOQ 适用于对一种或多种肿瘤坏死因子（TNF）阻滞剂反应不足或不耐受的中度至重度活动性UC或CD成人。此次标签更新赋予医疗专业人员更大的灵活性，当TNF阻滞剂在临床上不可取时，他们可以在早期阶段为在接受至少一种批准的全身治疗后的患者选择Rinvoq，从而优化个体化治疗策略。 Rinvoq是一种选择性JAK抑制剂，通过抑制特定细胞信号通路(JAK-STAT)发挥作用。自2019年获批用于治疗对甲氨蝶呤反应不足或不耐受的中重度活动性类风湿关节炎成人患者以来，Rinvoq不断拓展其适应症范围，在多个免疫介导性疾病领域展现出显著的治疗效果。目前已获批多项FDA适应症，包括类风湿关节炎、银屑病关节炎、特应性皮炎、溃疡性结肠炎、克罗恩病等。此外，Rinvoq还在拓展更多适应症，包括：白癜风、化脓性汗腺炎、系统性红斑狼疮。业内分析师Matt Phipps评价称：“这些潜在新适应症有望为Rinvoq带来额外20亿美元的峰值销售额。而随着每一项新适应症的获批，其专利与数据保护期也相应延长，商业价值将进一步放大。” 这一系列进展的背后，是艾伯维应对“药王”Humira（阿达木单抗）专利到期挑战的核心战略布局。Humira曾连续十年蝉联全球最畅销药物榜首，年销售额峰值超200亿美元。然而，随着多个生物类似药在美国市场的涌入，其销售额自2023年起持续下滑，2024年已不足百亿美元。在此背景下，Rinvoq被寄予厚望。数据显示，2025年上半年，Rinvoq全球销售额已达37.5亿美元，其中美国市场贡献约27亿美元。公司预计，全年销售额有望突破75亿美元，展现出强劲的增长动能，成为“药王的继承者”。更值得瞩目的是，2025年9月，艾伯维通过与多家仿制药企业的和解协议，成功将Rinvoq在美国的市场独占期延长至2037年4月。该协议确保在假设获得儿科独占权的前提下，仿制药无法在美国上市，此举预计将为公司额外带来40至50亿美元的峰值收入，为其长期增长提供坚实保障。没有永恒的药王，只有永恒的创新。业内专家指出，Rinvoq的持续适应症扩展与专利策略的双重推进，不仅巩固了其在免疫治疗领域的领先地位，也彰显了艾伯维在研发管线延续性、生命周期管理和商业策略上的深远布局。参考资料： 1.https://www.prnewswire.com/news-releases/us-food-and-drug-administration-fda-approves-updated-indication-statement-for-rinvoq-upadacitinib-for-the-treatment-of-inflammatory-bowel-disease-302582159.html 2.艾伯维官网 3.其他公开资料图片来源：即梦AI 全球首款！TROP2 ADC又一适应症获批 2025-10-13 2.5亿美元即将到账！百利天恒与BMS合作达到里程碑 2025-10-12 又一MNC终止细胞治疗研发 2025-10-11 版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击查看更多精彩内容！

专利到期一致性评价上市批准生物类似药

2025-10-14

·Pharmaceutical Technology

FDA approves AbbVie’s Rinvoq for inflammatory bowel disease

The JAK inhibitor is currently under investigation for a range of immune-mediated inflammatory diseases. Credit: SmartPhotoLab/Shutterstock.com. The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication statement for Rinvoq (upadacitinib) to treat inflammatory bowel disease. This approval relates to the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD). AbbVie’s revised indication permits the use of the therapy for patients who have undergone at least one approved systemic therapy, when tumour necrosis factor (TNF) blockers are deemed clinically unsuitable. Rinvoq was previously indicated for adults with moderately to severely active UC or CD who had not responded adequately or were intolerant to one or more TNF blockers. AbbVie global immunology clinical development head and vice-president Kori Wallace stated: “At AbbVie, we are committed to addressing the ongoing needs of patients living with inflammatory bowel disease. Ulcerative colitis and Crohn’s disease can impact every aspect of a patient’s life. “This label update gives healthcare providers the option to prescribe RINVOQ for patients with moderately to severely active inflammatory bowel disease after the use of one approved systemic therapy if TNF blockers are deemed clinically inadvisable by the prescribing physician.” GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Rinvoq is a Janus kinase (JAK) inhibitor currently under investigation for a range of immune-mediated inflammatory diseases. It is being evaluated in Phase III studies for conditions such as Takayasu arteritis, hidradenitis suppurativa, alopecia areata, vitiligo and systemic lupus erythematosus. Rinvoq is also a prescription medicine for treating adults with moderate to severe rheumatoid arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis with objective inflammation signs. Other indications include active psoriatic arthritis, and giant cell arteritis when TNF blockers prove inadequate or intolerable. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

临床3期上市批准

2025-10-13

·米内网

【聚焦】跨国制药公司管线分析：预见交易方向、预见重磅药物

精彩内容深度研究报告《跨国制药公司的管线分析——预见交易方向、预见重磅药物》对17家跨国制药企业的重磅产品市场与专利到期风险、临床研发管线、交易动向及近五年专利布局进行了系统分析，旨在科学预测各企业的管线策略、引进需求、潜在重磅药物及早期潜力靶点，为创新药企的研发立项、策略制定与业务合作提供参考。 10月10日晚上，濠麦科技成功举办了《跨国制药公司的管线分析：预见交易方向、预见重磅药物》线上报告分享会，吸引了160家企业代表参与。为便于未到场嘉宾掌握报告精华，现将核心洞见整理分享。报告分析架构（17个子报告+1个总报告）报告核心发现（部分举例）：全球药企面临三大生死挑战 ★专利悬崖海啸到2030年，全球将有超过2600亿美元的市场面临专利到期风险，涉及Keytruda、Ozempic等超过30种重磅药物。这一危机已迫在眉睫：BMS的Eliquis将于2026年到期，默沙东的Keytruda在2028年面临挑战，而强生的Stelara专利保护已失效。各大企业正迫切寻求快速推进或引进后期管线以应对挑战。面对压力，行业已出现成功范例。艾伯维通过推动自免管线迭代，以Skyrizi和Rinvoq成功接棒Humira的专利悬崖；强生在自免领域面临百亿美元市场缺口之际，也正通过新一轮产品布局开启发展新阶段。表1：专利悬崖对MNC重磅药物销售影响表2：自免领域MNC重磅药物美国专利到期 ★管线布局结构性矛盾（举例）自免领域：COPD、斑秃等中国高发疾病在研药物严重不足。代谢领域：当前研发管线高度集中于GLP-1R等少数靶点，而新靶点探索相对匮乏。这一现状正驱动行业向两大方向寻求突破：一是积极探索全新靶点；二是在现有靶点基础上，着力开发新老靶点组合、长效制剂、小核酸药物及口服制剂等差异化技术路径…… 报告洞见：前瞻性战略决策指南 1.技术平台交易并购风向标（举例）通过濠麦专利数据挖掘，进一步探寻ADC创新方向： ★双靶点方向 WO2025167503A1（SEZ6/B7-H3）、WO2025131063A1（B7-H3/TROP2）、WO2023215737A1（CD3/Ly6E、罗氏）......... ★新Payload方向 Bcl-xL抑制剂通过阻断抗凋亡蛋白诱导癌细胞程序性死亡，如艾伯维的ABBV-155通过靶向EGFR以降低血小板毒性，并在临床研究中展现出对实体瘤的治疗潜力。PROTAC分子利用蛋白酶体降解机制，为ADC药物引入“蛋白降解”功能，有望克服传统载荷的耐药问题。此外，诸如TOP1与TLR7/8抑制剂等机制组合正受到越来越多关注，其目标在于联动细胞毒性作用与免疫激活效应，以重塑肿瘤微环境，该类联合策略仍在持续拓展。其他值得关注的专利方向还包括Mcl-1抑制剂（如罗氏WO2025106634A1）、ALK5抑制剂（WO2024258967A1）以及GLP-1R激动剂（如辉瑞WO2025096921A1、WO2025104668A1）等。 2.交易预见 2.1技术平台为例 2.2 MNC交易需求特点、偏好及潜在需求目标分析与洞见（以罗氏为例）布局领域：核心领域为肿瘤、自免、神经、血液、眼科；拓展领域为CVRM ★交易核心的驱动因素 1）CD20和HER2面临的天花板效应 2）2028-2033年专利悬崖持续影响 ★交易需求特点 1）正在由“肿瘤主导”向多元化发展转型 2）深耕CD20、HER2、IL-6靶点，BIC管线、迭代管线 3）中小型交易为主，并购为辅 4）早期+后期资产均重视 ★交易需求洞见肿瘤方向： 1）巩固乳腺癌优势，强化血液瘤，拓展非小细胞肺癌 2）缺乏三阴乳腺癌管线 3）Trop-2，HER3、FRα、LIV-1、ROR1等靶点的双抗/多抗或ADC 4）CD20、CD79b双抗、多抗、TEC、ADC、CAR-T 5）有BIC潜力的靶向CD19、CD22、CD33、BCMA等靶点的ADC、CAR-T、TCE 6）EGFR双抗或ADC药物，如EGFR/HER3 ADC、EGFR/c-MET ADC等 7）PD-1/VEGF、（PD-(L)1/VEGF/CTLA4、PD-(L)1/cytokines等自免领域： 1）IBD、COPD、AD、MS、SLE、IgA肾病等多个细分疾病领域 2）TL1A双抗或小分子药物、STAT6降解剂、PDE4/PDE3抑制剂、CD19 CAR-T，以及IL-4R、IL-5、IL-33R靶点组合双抗等 CVRM： 1）肥胖、MASH2）AMYR类小分子 3）心衰、血脂异常、血栓栓塞 4）factor XI、lipoprotein(a)、PCSK9、ApoC3 RNAi疗法、THR-β/ASGPR 3.重点疾病领域的管线布局立项机会（以自免为例） 3.1四大价值洼地疾病 3.2以自免领域为例——治疗现状及未被满足需求 3.3靶点全景图与竞争热点图 3.4重磅靶点的差异化机会（TL1A靶点，自免领域新核弹为例）临床价值：溃疡性结肠炎12周临床缓解率提升25倍（NEJM 2024）交易狂潮：默沙东108亿美元、罗氏72亿美元、艾伯维17亿美元接连押注濠麦专利大数据挖掘，下一代迭代方向： ★半衰期延长技术（明济生物专利超过800小时） ★双靶点组合（TL1A×IL-23、TL1A×p40.......） ★口服TL1A 研究方法论：完善、严谨的数据挖掘引擎交付价值：企业战略生存工具箱基础套件 ★17份MNC专项报告（平均5万字/家）+汇总报告（近10万字） ★管线布局/专利悬崖与交易预见/靶点立项 ★每季度进行汇总更新战略会员另外专享 ★立项、研发策略、投资洞见动态系统 ★每月专利解析——前沿技术专利地图 ★每月重点疾病领域（肿瘤、代谢、自免等，不断拓展）：立项靶点或药物建议洞见；终止/暂停靶点或药物预警洞见 ★季度追踪：MNC管线终止/引进风险标红获取完整战略洞察，联系洞见团队王梦洋手机：15251766189 邮件：jeremy.wang hq-haomai.com 免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

抗体药物偶联物专利到期蛋白降解靶向嵌合体并购

100 项与乌帕替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10994 D11048	乌帕替尼	L04AA44	DB15091

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
巨细胞动脉炎	欧盟	AbbVie Deutschland GmbH & Co. KG	2025-04-08
巨细胞动脉炎	冰岛	AbbVie Deutschland GmbH & Co. KG	2025-04-08
巨细胞动脉炎	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2025-04-08
巨细胞动脉炎	挪威	AbbVie Deutschland GmbH & Co. KG	2025-04-08
多关节型幼年特发性关节炎	美国	AbbVie, Inc.	2024-04-26
活动性中度克罗恩病	欧盟	AbbVie Deutschland GmbH & Co. KG	2023-04-24
活动性中度克罗恩病	冰岛	AbbVie Deutschland GmbH & Co. KG	2023-04-24
活动性中度克罗恩病	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2023-04-24
活动性中度克罗恩病	挪威	AbbVie Deutschland GmbH & Co. KG	2023-04-24
活动性重度克罗恩病	欧盟	AbbVie Deutschland GmbH & Co. KG	2023-04-24
活动性重度克罗恩病	冰岛	AbbVie Deutschland GmbH & Co. KG	2023-04-24
活动性重度克罗恩病	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2023-04-24
活动性重度克罗恩病	挪威	AbbVie Deutschland GmbH & Co. KG	2023-04-24
中度特应性皮炎	美国	AbbVie, Inc.	2022-01-14
重度特应性皮炎	美国	AbbVie, Inc.	2022-01-14
克罗恩病	加拿大	AbbVie AS	2020-01-16
强直性脊柱炎	欧盟	AbbVie Deutschland GmbH & Co. KG	2019-12-16
强直性脊柱炎	冰岛	AbbVie Deutschland GmbH & Co. KG	2019-12-16
强直性脊柱炎	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2019-12-16
强直性脊柱炎	挪威	AbbVie Deutschland GmbH & Co. KG	2019-12-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
睡眠异常	临床3期	-	AbbVie, Inc.	2024-05-23
非节段型白癜风	临床3期	美国	AbbVie, Inc.	2023-12-19
非节段型白癜风	临床3期	中国	AbbVie, Inc.	2023-12-19
非节段型白癜风	临床3期	日本	AbbVie, Inc.	2023-12-19
非节段型白癜风	临床3期	阿根廷	AbbVie, Inc.	2023-12-19
非节段型白癜风	临床3期	比利时	AbbVie, Inc.	2023-12-19
非节段型白癜风	临床3期	保加利亚	AbbVie, Inc.	2023-12-19
非节段型白癜风	临床3期	加拿大	AbbVie, Inc.	2023-12-19
非节段型白癜风	临床3期	智利	AbbVie, Inc.	2023-12-19
非节段型白癜风	临床3期	法国	AbbVie, Inc.	2023-12-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03569293 \| NCT03345823 \| NCT03607422 \| NCT03104400 \| NCT03086343 \| NCT03568318 \| NCT02819635 \| NCT03178487 \| NCT02675426 \| NCT02629159 \| NCT03104374 \| NCT04169373 \| NCT02706951 \| NCT02706873 \| NCT02706847 (Pubmed \| Adv Ther)	N/A	银屑病关节炎 \| 类风湿关节炎 \| 中轴性脊柱关节炎 ... 更多	8,632	Upadacitinib (Psoriatic Arthritis)	廠齋夢願範廠膚齋製觸(憲鹹夢艱鏇窪網醖壓齋) = 選製鏇鏇鏇簾衊糧鏇築製醖遞憲網夢壓廠獵範 (窪蓋繭簾觸糧選願餘鹹 ) 更多	积极	2025-10-01
				Upadacitinib (Axial Spondyloarthritis)	襯構製選醖襯積蓋鹹衊(醖鬱鏇鹹夢糧夢餘廠繭) = 鹽鏇淵鏇蓋淵築網襯鹹範製願艱蓋醖糧獵衊醖 (鏇齋鏇鬱獵觸觸選窪鏇 ) 更多
NCT03345823 (U-ENDURE, Pubmed \| J Crohns Colitis)	临床3期	克罗恩病引起的肛周瘘维持	228	Upadacitinib 15 mg	夢齋壓醖淵願膚鹽獵夢(餘選淵顧製願構膚餘鹽) = ≥ 5.0 events/100 person-years 獵壓簾鹹餘製顧範壓襯 (鑰願簾製積積廠遞鹹鑰 ) 更多	积极	2025-09-07
				Upadacitinib 30 mg
NCT03568318 \| NCT03569293 \| NCT03607422 (MeUp1, Pubmed \| Am J Clin Dermatol)	临床3期	特应性皮炎	2,782	Upadacitinib 15 mg (with/without topical corticosteroids)	艱鹹積選淵鏇選窪繭鏇(艱獵築選糧憲糧艱獵醖) = 夢蓋製壓築襯衊簾壓製膚簾選艱繭鹹艱繭願構 (憲鹹構鬱淵鑰獵廠衊蓋 ) 更多	积极	2025-09-03
				Upadacitinib 30 mg (with/without topical corticosteroids)	艱鹹積選淵鏇選窪繭鏇(艱獵築選糧憲糧艱獵醖) = 淵鏇衊糧憲網鹹淵選膚膚簾選艱繭鹹艱繭願構 (憲鹹構鬱淵鑰獵廠衊蓋 ) 更多
NCT06012240 (UP-AA, Company_Website) 人工标引	临床3期	斑秃	397	Upadacitinib 15 mg (Study 1)	淵艱顧壓窪鏇蓋蓋範壓(顧窪夢構鏇遞繭醖遞夢) = 鹹窪鏇網鹽憲繭糧壓齋範齋鏇壓艱觸積遞製範 (鹹顧鏇鏇鹹鏇淵憲衊夢 ) 达到更多	积极	2025-08-22
				Upadacitinib 30 mg (Study 1)	淵艱顧壓窪鏇蓋蓋範壓(顧窪夢構鏇遞繭醖遞夢) = 蓋襯淵鏇壓積觸鏇網願範齋鏇壓艱觸積遞製範 (鹹顧鏇鏇鹹鏇淵憲衊夢 ) 达到更多
NCT06012240 (UP-AA M23-716, Company_Website) 人工标引	临床3期	斑秃	1,399	Upadacitinib 15 mg (Study 2)	鑰醖觸願獵艱鑰積繭蓋(網顧遞憲艱選鹽窪積製) = 獵願範窪積鬱積壓鹽網廠鏇網遞鏇鏇壓鹽願鹹 (範積膚願艱糧積鹽衊觸 ) 达到更多	积极	2025-07-30
				Upadacitinib 30 mg (Study 2)	鑰醖觸願獵艱鑰積繭蓋(網顧遞憲艱選鹽窪積製) = 網膚艱製繭膚鑰廠憲鏇廠鏇網遞鏇鏇壓鹽願鹹 (範積膚願艱糧積鹽衊觸 ) 达到更多
NCT05507580 (Flex-Up, CTgov)	临床4期	中度特应性皮炎 \| 重度特应性皮炎	461	Upadacitinib (UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period)	獵窪遞衊廠繭衊鬱憲觸 = 顧簾糧壓膚鏇膚願構窪簾構簾遞鹹獵淵製鑰廠 (製遞齋廠餘齋鹽衊齋廠, 醖繭網齋窪蓋鬱遞蓋獵 ~ 衊鑰構簾餘膚鹹製遞繭) 更多	-	2025-07-29
				Upadacitinib (UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period)	獵窪遞衊廠繭衊鬱憲觸 = 鹹遞獵鬱選鏇鏇製糧醖簾構簾遞鹹獵淵製鑰廠 (製遞齋廠餘齋鹽衊齋廠, 製襯選襯膚糧窪鹽鏇鹽 ~ 廠壓齋膚顧糧糧餘鹽網) 更多
NCT03607422 (Measure Up 2, Pubmed \| Dermatol Ther (Heidelb))	临床3期	特应性皮炎	1,683	Upadacitinib 15 mg	窪選選願鹹蓋壓蓋廠廠(艱蓋願繭築餘鏇鹽壓製) = 糧選遞積遞廠鹽襯範製衊醖顧淵鏇艱膚憲蓋積 (蓋鏇鹽選衊鏇鹹遞範蓋 ) 更多	积极	2025-07-14
				Upadacitinib 30 mg	窪選選願鹹蓋壓蓋廠廠(艱蓋願繭築餘鏇鹽壓製) = 網築膚淵醖鑰蓋範鑰願衊醖顧淵鏇艱膚憲蓋積 (蓋鏇鹽選衊鏇鹹遞範蓋 ) 更多
NCT02819635 \| NCT03653026 (U-ACHIEVE and U-ACCOMPLISH, Pubmed \| J Crohns Colitis)	临床3期	活动性重度溃疡性结肠炎维持	-	Upadacitinib 45 mg	鑰齋簾淵獵壓淵顧範淵(範簾淵構醖鏇鏇積憲顧) = 範獵壓鑰觸願製餘觸構鏇餘積衊壓壓網鹽鬱窪 (繭廠積築願壓願壓鏇鹽 ) 更多	积极	2025-07-03
				Upadacitinib 30 mg	鑰齋簾淵獵壓淵顧範淵(範簾淵構醖鏇鏇積憲顧) = 鹽製壓鬱觸醖鹽觸觸鏇鏇餘積衊壓壓網鹽鬱窪 (繭廠積築願壓願壓鏇鹽 ) 更多
EULAR2025	N/A	涎腺多形性腺瘤	425	Upadacitinib 15 mg	鹹鏇簾廠構繭醖選簾獵(窪衊繭鏇範願範壓簾範) = 簾憲鏇範製鹹遞鑰艱鏇蓋觸鹽網餘網襯醖願選 (願網築蓋糧壓膚艱醖蓋 )	积极	2025-06-11
NCT03104400 (SELECT-PsA 1, EULAR2025)	临床3期	银屑病关节炎	640	Upadacitinib 15mg (non-bDMARD-IR)	簾窪選襯鏇鹽選鑰鹽醖(築獵鑰觸窪製淵遞淵選) = a larger proportion of patients with early pain improvements achieved MDA, DAPSA LDA, and pain ≤1.5 at wk 152, compared to patients without early pain improvements. 蓋製遞選範顧艱鬱築艱 (夢蓋窪襯鏇蓋願觸壓構 )	积极	2025-06-11
				Upadacitinib 15mg (bDMARD-IR)